Kentucky health officials warn against use of kratom
LEXINGTON, Ky. (FOX 56) — Kratom is a tropical tree found in Southeast Asia, and it has been around for hundreds of years. Its leaves are sold throughout the United States and can treat things like pain, coughing, anxiety, depression, and even opioid use disorder and withdrawal.
'It is sold in Kentucky. Usually, it will come in either an herbal powder form or in a pill form,' said Program Director for Voices of Hope Lexington, Jimmy Chadwell.
Kentucky health officials warn against use of kratom
Kentucky judge tells lawmakers child removal process doesn't move quick enough in abuse investigations
1 charged, shelter-in-place ended in Saunders Lane after Boone County shooting investigation
In early June, the Kentucky Department for Public Health and the Kentucky Office of Drug Control Policy put out a health alert advising the public not to consume kratom products and products containing 7-hydroxymitragynine, better known as 7-OH. It is a chemical compound found in kratom.
The health agencies warned that when 7-OH is concentrated or synthetically made, it can increase the risk of overdose, severe health issues, and death.
Chadwell urges those using pure kratom products for their harm-reduction benefits to do so wisely.
Kentuckians spend the 3rd highest share of their income on fast food
Bill could make federal minimum wage $15: Kentucky among states paying less than that
Kentucky sitting near bottom of rankings in environmental protection: Study
'Exercise caution. Moderate the amount you use. Never use it alone. Always have Narcan available. Okay? Because of these kratom and the 7-OH, they work on the opioid receptors. So having Narcan available is really going to save somebody's life,' he told FOX 56.
Kratom is not FDA-approved and is illegal in six states.
But Chadwell said that Voices of Hope, an organization for people recovering from substance abuse disorders, believes the answer is not more laws; it is more conversation.
'We believe that creating more laws surrounding drugs and drug users will not help the community. Instead, we feel that supporting increases in the availability of education and encouraging harm reduction initiatives when using any substance are the best route to go,' he said.
Read more of the latest health and wellness news
Health officials also said there are no guarantees that kratom products contain the ingredients the packages claim, have the correct concentrations, or are free from contaminants or other drugs.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding
Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status COLUMBIA, Md., June 13, 2025 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, today submitted written testimony to the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies through its chief executive officer, Jason Menzo, who served as an expert outside witness. In the testimony, Menzo urged the Subcommittee to deliver robust and sustained funding for the National Eye Institute (NEI) in Fiscal Year 2026 and to preserve NEI's status as an independent institute within the National Institutes of Health (NIH). "NEI is the only federal institute dedicated exclusively to vision research," said Jason Menzo, CEO of the Foundation Fighting Blindness. "Its work is restoring sight, advancing precision medicine, and delivering hope to millions of Americans living with retinal diseases. Continued investment is critical to maintaining momentum and achieving breakthroughs for conditions that currently have no cure." The Foundation's testimony highlights how NEI-supported research has led to transformative discoveries, including the first FDA-approved gene therapy for an inherited disease, and emphasizes NEI's strategic role in public-private collaborations that accelerate treatment development. The Foundation Fighting Blindness and NEI have long shared a close, collaborative partnership to advance high-impact scientific discovery and bring new treatments to patients faster. Vision loss from diseases such as retinitis pigmentosa, macular degeneration, and Stargardt disease currently affects tens of millions and costs the U.S. economy an estimated $134.2 billion annually. The Foundation emphasized that inconsistent funding stalls clinical trials, closes labs, and risks losing top scientific talent—consequences that are difficult and costly to reverse. The testimony also noted that for every dollar invested in NIH-funded research, $2.56 in new economic activity is generated, making this one of the highest-return investments Congress can make. "We're not just talking about restoring sight—we're talking about protecting America's leadership in biomedical innovation and supporting economic growth in communities nationwide," added Menzo. The Foundation Fighting Blindness urges Congress to: Provide strong, sustained funding for NEI in the FY2026 Labor-HHS Appropriations bill; and Preserve NEI's status as an independent institute within NIH to ensure focused, strategic investment in vision science. The full testimony is available at About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private source of funding for research on retinal degenerative diseases. The Foundation has raised over $954 million toward its mission to prevent, treat, and cure blinding diseases such as retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and more. Visit for more information. Media Contacts:Chris AdamsVice President, Marketing & CommunicationsCAdams@ 423-0585 View original content to download multimedia: SOURCE Foundation Fighting Blindness
Bloomberg
an hour ago
- Bloomberg
FDA Tells Drugmaker ‘Heavy Workload' to Delay Approval Decision
US regulators delayed their decision on whether to approve the first pill taken on demand for a rare, inherited swelling disorder due to a 'heavy workload and limited resources,' a biotech company said. The US Food and Drug Administration told KalVista Pharmaceuticals Inc. that it won't meet a June 17 deadline to take action on sebetralstat, the company said in a statement. The agency didn't request additional studies or raise concerns about the drug for hereditary angioedema, a condition that causes painful and potentially life-threatening swelling episodes in different parts of the body, it said.
Yahoo
3 hours ago
- Yahoo
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks CAMBRIDGE, Mass. & SALISBURY, England, June 13, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the Company believes the only remaining item under FDA review is the finalization of the labelling. "We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks," said Ben Palleiko, CEO of KalVista. "At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering." About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older and are investigating its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Ryan BakerHead, Investor Relations(617) Molly CameronDirector, Corporate Communications(978) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
